Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer

• Main Authors: Tony S. Mok, S. L. Geater, N. Iannotti, S. Thongprasert, A. Spira, D. Smith, V. Lee, W. T. Lim, L. Reyderman, B. Wang, P. Gopalakrishna, F. Garzon, L. Xu, C. Reynolds
• 格式: 雜誌
• 出版: 2018
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84905162106&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/45827

Background: This phase II, open-label study investigated intercalated combinations of eribulin and erlotinib in unselected patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapies. Patients and methods: Eligible patients were randomized to eribulin mesy...